Sugi Predict

Sugi Predict / Compounds / SCHEMBL6991920

SCHEMBL6991920

SCHEMBL6991920

N[C@@H]1C[C@H]1c1ccc(Cl)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 15/20 0.60
▸ MAOB P27338 12/20 0.60
▸ KCNH2 Q12809 3/20 0.60
▸ RCOR1 Q9UKL0 3/20 0.60
▸ KDM1B Q8NB78 2/20 0.60
▸ MAOA P21397 7/20 0.58
▸ CYP2C19 P33261 4/20 0.58
▸ CYP2B6 P20813 3/20 0.58
▸ CYP1A2 P05177 2/20 0.58
▸ CYP2D6 P10635 2/20 0.58
▸ CYP2C9 P11712 2/20 0.58
▸ LMNA P02545 2/20 0.58
▸ TAAR1 Q96RJ0 2/20 0.58
▸ HTR2C P28335 2/20 0.58
▸ CYP3A4 P08684 1/20 0.58
▸ HTR1A P08908 1/20 0.58
▸ ADRA2A P08913 1/20 0.58
▸ CYP2A6 P11509 1/20 0.58
▸ SLC6A2 P23975 1/20 0.58
▸ ADRA1A P35348 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2837243 1.00 KDM1A (0.60) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL7509170 1.00 KDM1A (0.60) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL2835482 1.00 KDM1A (0.60) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL7509163 1.00 KDM1A (0.60) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL6991918 1.00 KDM1A (0.60) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL31113844 1.00 KDM1A (0.60) KDM1AMAOBKCNH2RCOR1KDM1B
Hydrochloric Acid SCHEMBL1570164 0.98 KDM1A (0.61) KDM1AMAOBKCNH2RCOR1KDM1B
Hydrochloric Acid SCHEMBL2217941 0.98 KDM1A (0.61) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL19596183 0.93 KDM1A (0.67) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL530132 0.93 KDM1A (0.67) KDM1AMAOBKCNH2RCOR1KDM1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024186915-A1 DUAL-TARGET MU OPIOID AND DOPAMINE D3 RECEPTORS LIGANDS PREPARATION AND USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2024-09-12 — — WO disclosed
EP-2688568-B1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2019-06-19 — — EP disclosed
US-10064854-B2 Cyclopropylamines as LSD1 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-09-04 — — US disclosed
US-20180000805-A1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-01-04 — — US disclosed
US-9795597-B2 Cyclopropylamines as LSD1 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-10-24 — — US disclosed
US-20160220547-A1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-08-04 — — US disclosed
US-9346840-B2 Cyclopropylamines as LSD1 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2016-05-24 — — US disclosed
US-20140371176-A1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2014-12-18 — — US disclosed
US-8853408-B2 Cyclopropylamines as LSD1 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2014-10-07 — — US disclosed
EP-2688568-A2 CYCLOPROPYLAMINES AS LSD1 INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2014-01-29 — — EP disclosed
US-20140018393-A1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS Glaxo Smith Kline LLC 2014-01-16 — — US disclosed
WO-2012135113-A2 CYCLOPROPYLAMINES AS LSD1 INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-10-04 — — WO disclosed
EP-0996621-B1 TRIAZOLO[4,5-d]PYRIMIDINE DERIVATIVES AS ANTI-THROMBOTIC AGENTS ASTRAZENECA AB (SE) 2003-10-01 — — EP disclosed
EP-1097153-B1 NOVEL TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS ASTRAZENECA AB (SE) 2003-10-01 — — EP disclosed
EP-1056749-B1 NOVEL TRIAZOLO(4,5-d)PYRIMIDINE COMPOUNDS ASTRAZENECA UK LTD (GB) 2003-02-19 — — EP disclosed
US-6369064-B1 MYOCARDIAL INFARCTION AND UNSTABLE ANGINA; P2T-RECEPTOR ANTAGONISTS; ANTITHROMBOTIC AGENTS; 7-(SUBSTITUTED AMINO) -5-(THIO)-3H-1,2,3-TRIAZOLO(4,5-D)PYRIMIDIN-3-YL) -CYCLOPENTANECARBOXAMIDES ASTRAZENECA AB (SE) 2002-04-09 — — US disclosed
EP-0946561-B1 TRIAZOLO(4,5-D)PYRIMIDINYL DERIVATIVES AND THEIR USE AS MEDICAMENTS ASTRAZENECA AB (SE) 2002-02-13 — — EP disclosed
US-6297232-B1 TREATMENT OF PLATELET AGGREGATION DISORDERS. ASTRAZENECA AB (SE) 2001-10-02 — — US disclosed
US-6251910-B1 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists ASTRAZENECA UK LIMITED (GB) 2001-06-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10064854-B2 Cyclopropylamines as LSD1 inhibitors KDM1B, KDM1A, KDM3B KDM1A 2/4885MAOB 200/4885KCNH2 2006/4885
US-20160220547-A1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS KDM1B, KDM1A, KDM3B KDM1A 2/4885MAOB 200/4885KCNH2 2006/4885
US-20140018393-A1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS KDM1B, KDM1A, KDM3B KDM1A 2/4885MAOB 200/4885KCNH2 2006/4885
US-20180000805-A1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS KDM1B, KDM1A, KDM3B KDM1A 2/4885MAOB 200/4885KCNH2 2006/4885
US-20140371176-A1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS KDM1B, KDM1A, KDM3B KDM1A 2/4885MAOB 200/4885KCNH2 2006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.